TAG overview

Personalized Medicine

A patient journey: starting with questions

Chinese Version Skip


George was diagnosed with late-stage colorectal cancer at the age of 54. Naturally, his life changed immediately and he wanted answers to important questions: What are my chances? What is the right treatment? How will disease and therapy affect my life from now on?

Innovations in medical research help in finding answers to these questions quicker than ever before.

Every patient counts

The solution: tailored to each individual patient



Finding the right therapy can be a long road of trial and error. But George’s doctors used a specific diagnostic approach. They were able to quickly test whether a therapy they thought would be the right treatment option would be effective for him.

Thankfully, the tests showed that the treatment could work for him based on the genetic makeup of his disease. Because the treatment was personalized according to the patient’s need, George was able to start the fight against colorectal cancer as quickly and effectively as possible, increasing his chances of beating the disease.

Learn more

George’s experience is a fictional example. But there are millions of real people searching for answers to the question of how to treat their disease as effectively as possible. Personalized medicine aims to tailor unique treatment options to patients who share characteristics and who therefore are most likely to benefit from the treatment. We are committed to advancing this personalized medicine approach and to make it as widely available as possible.

Effectively treating cancer

Worldwide, about 1.2 million people develop colorectal cancer every year and the disease causes over 600,000 human deaths annually. A complex biological signaling cascade is involved in the development and progression of this cancer type. In order to block this cancer-promoting signaling cascade, scientists developed so-called selective . When these antibodies bind with the growth receptor, the cancer cell no longer receives the messages it needs for growth, progression and metastasis. This treatment approach has the potential to ultimately lead to high response rates and a clinically meaningful benefit in patients identified to be promising treatment candidates. This is usually done by using biomarkers to test whether the patient can respond to a certain therapy.


Scientists and medical professionals know that people react differently to therapies. Some patients respond well to a treatment, others not at all or the treatment may cause adverse effects. The challenge is to find out which treatment fits best to the person in question and what approach has the most promising outcome. Technological advances such as (e.g. blood-based next generation sequencing) make it easier for patients to undergo tests to find the right fit of treatment. In contrast to traditional invasive tumor biopsies that remove part of the tissue in order to analyze it, liquid biopsies can deliver comparable or additional information by testing body fluids that can be obtained in convenient manner. The derived information provides guidance on which treatment option will probably be most effective, whether a patient might respond to a specific treatment or whether a patient is likely to experience tumor progression.

Our vision for personalized medicine is that every patient takes the type and dosage of medicine that is best suited for their personal circumstances. This may lead to a better quality of life. After all, why should you administer three injections a day if the body in question only needs two?

Making science tangible:
Read our "Envisioning tomorrow" stories, which deal with the most pressing issues of our time. Meet our scientists, surf through thousands of scientific publications, patents and presentations.

The same method of treating colorectal cancer is not effective in all patients. But with personalized medicine, a specially developed predictive biomarker can indicate the expected efficacy of the therapy – allowing treating physicians to prescribe it only to those patients who can actually significantly benefit from the therapy.

Precision medicine
More in our
science space

The goal: improve treatment success rates

Conventional drugs are currently effective in…

25% of all cancer patients
30% of people with Alzheimer’s disease
50% of patients with diabetes

If, in the future, targeted approaches can be used to treat more illnesses, this can lead to a wide range of economic, social and environmental benefits: Lower failure rates of therapies reduce the financial burden on the health system. More precisely targeted medication can decrease the likelihood of patients developing resistances which could increase the likelihood of successful future therapies. Also, using less medication would cause less residual medical ingredients to enter the water treatment cycle and the environment.

The right drug for the right patient

Lisa Benincosa

Head of Global Translational Medicine

Lisa Benincosa is Head of Global Translational Medicine at our company. Translational Medicine is a multidisciplinary area of research that aims to improve human health and longevity by determining the relevance to human disease of novel discoveries in the biological sciences.

Education: PhD Pharmaceutical Sciences, University at Buffalo, State University of New York
Joined our company in: July 2019
Focus areas: Clinical Pharmacology

Our commitment to the SDGs

Promote well-being for all at all stages

The effort we put into researching and further developing personalized medicines aligns with targets of United Nations Sustainable Development Goal 3: By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being.

Personalized medicines can help decrease the mortality rate attributed to cancer. When a patient is diagnosed at an advanced disease stage, timely and evidence-based treatment selection is critical. Our research aims to enable the physician to select an appropriate treatment based on molecular information, potentially reducing side effects, improving tolerability and quality of life and finally increasing the chances of healing and survival.

Personal Medicine Quote (photo)

The combined efforts of global healthcare will turn scientific insights into superior and affordable therapeutic concepts, with sustainable value for patients and society. Personalized medicine is a very promising avenue of this effort.”

Jürgen Scheuenpflug Global Head Clinical Biomarkers & Companion Diagnostics

Monoclonal antibodies
Monoclonal antibodies are proteins that specifically recognize and bind to other unique proteins called antigens.
Liquid biopsy
Sampling and analysis of non-solid biological tissue such as blood.
People or organizations that have a legitimate interest in a company, entitling them to make justified demands. Stakeholders include people such as employees, business partners, neighbors in the vicinity of our sites, and shareholders.


Cookie Disclaimer

This website uses 'cookies' to give you the best, most relevant experience. Using this website means you’re OK with this. You can change which cookies are set at any time - and find out more about them in our cookie policy. Privacy Statement